Literature DB >> 26738480

Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet?

Swetha Rudraiah1, Xi Zhang1, Li Wang1,2,3.   

Abstract

Nuclear receptors (NR) are ligand-modulated transcription factors that play diverse roles in cell differentiation, development, proliferation, and metabolism and are associated with numerous liver pathologies such as cancer, steatosis, inflammation, fibrosis, cholestasis, and xenobiotic/drug-induced liver injury. The network of target proteins associated with NRs is extremely complex, comprising coregulators, small noncoding microRNAs, and long noncoding RNAs. The importance of NRs as targets of liver disease is exemplified by the number of NR ligands that are currently used in the clinics or in clinical trials with promising results. Understanding the regulation by NR during pathophysiological conditions, and identifying ligands for orphan NR, points to a potential therapeutic approach for patients with liver diseases. An overview of complex NR metabolic networks and their pharmacological implications in liver disease is presented here.

Entities:  

Keywords:  cholestatic liver disease; drug-induced liver injury; hepatocellular cancer; liver inflammation and fibrosis; nonalcoholic fatty liver; viral hepatitis infection

Mesh:

Substances:

Year:  2016        PMID: 26738480      PMCID: PMC4919666          DOI: 10.1146/annurev-pharmtox-010715-103209

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  146 in total

Review 1.  The CAR nuclear receptor and hepatocyte proliferation.

Authors:  Robert H Costa; Vladimir V Kalinichenko; Vladimir V Kalinchenko; Yongjun Tan; I-Ching Wang
Journal:  Hepatology       Date:  2005-11       Impact factor: 17.425

2.  Activation of the farnesoid X receptor provides protection against acetaminophen-induced hepatic toxicity.

Authors:  Florence Ying Lee; Thomas Quad de Aguiar Vallim; Hansook Kim Chong; Yanqiao Zhang; Yaping Liu; Stacey A Jones; Timothy F Osborne; Peter A Edwards
Journal:  Mol Endocrinol       Date:  2010-06-23

3.  The orphan nuclear receptor SHP regulates PGC-1alpha expression and energy production in brown adipocytes.

Authors:  Li Wang; Jun Liu; Pradip Saha; Jiansheng Huang; Lawrence Chan; Bruce Spiegelman; David D Moore
Journal:  Cell Metab       Date:  2005-10       Impact factor: 27.287

4.  Decreased hepatic expression of PPAR-gamma coactivator-1 in cholesterol cholelithiasis.

Authors:  M Bertolotti; C Gabbi; C Anzivino; N Mitro; C Godio; E De Fabiani; M Crestani; M Del Puppo; M Ricchi; L Carulli; A Rossi; P Loria; N Carulli
Journal:  Eur J Clin Invest       Date:  2006-03       Impact factor: 4.686

5.  Effects of farnesoid X receptor on the expression of the fatty acid synthetase and hepatic lipase.

Authors:  Li-Li Shen; Hong Liu; Jiahe Peng; Lin Gan; Li Lu; Qian Zhang; Liangpeng Li; Fengtian He; Yu Jiang
Journal:  Mol Biol Rep       Date:  2010-04-07       Impact factor: 2.316

6.  CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice.

Authors:  Martin Wagner; Emina Halilbasic; Hanns-Ulrich Marschall; Gernot Zollner; Peter Fickert; Cord Langner; Kurt Zatloukal; Helmut Denk; Michael Trauner
Journal:  Hepatology       Date:  2005-08       Impact factor: 17.425

7.  Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids.

Authors:  Karine Hellemans; Peggy Verbuyst; Erik Quartier; Frans Schuit; Krista Rombouts; Ross A S Chandraratna; Detlef Schuppan; Albert Geerts
Journal:  Hepatology       Date:  2004-01       Impact factor: 17.425

8.  Novel role of nuclear receptor Rev-erbα in hepatic stellate cell activation: potential therapeutic target for liver injury.

Authors:  Ting Li; Ashley L Eheim; Sabine Klein; Frank E Uschner; Amber C Smith; Elizabeth Brandon-Warner; Sriparna Ghosh; Herbert L Bonkovsky; Jonel Trebicka; Laura W Schrum
Journal:  Hepatology       Date:  2014-04-29       Impact factor: 17.425

9.  Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.

Authors:  Mahmoud Khattab; Mohammed Emad; Asharf Abdelaleem; Mohammed Eslam; Rabab Atef; Yehia Shaker; Lamia Hamdy
Journal:  Liver Int       Date:  2009-11-16       Impact factor: 5.828

10.  Bile acids specifically increase hepatitis C virus RNA-replication.

Authors:  Patrick Chhatwal; Dorothea Bankwitz; Juliane Gentzsch; Anne Frentzen; Philipp Schult; Volker Lohmann; Thomas Pietschmann
Journal:  PLoS One       Date:  2012-04-25       Impact factor: 3.240

View more
  30 in total

1.  H19 promotes cholestatic liver fibrosis by preventing ZEB1-mediated inhibition of epithelial cell adhesion molecule.

Authors:  Yongfeng Song; Chune Liu; Xia Liu; Jocelyn Trottier; Michele Beaudoin; Li Zhang; Chad Pope; Guangyong Peng; Olivier Barbier; Xiaobo Zhong; Linheng Li; Li Wang
Journal:  Hepatology       Date:  2017-08-26       Impact factor: 17.425

2.  A Novel Small Molecule Activator of Nuclear Receptor SHP Inhibits HCC Cell Migration via Suppressing Ccl2.

Authors:  Zhihong Yang; Angela N Koehler; Li Wang
Journal:  Mol Cancer Ther       Date:  2016-08-02       Impact factor: 6.261

Review 3.  Circadian clock control of hepatic lipid metabolism: role of small heterodimer partner (Shp).

Authors:  Li Wang; Suthat Liangpunsakul
Journal:  J Investig Med       Date:  2016-07-29       Impact factor: 2.895

4.  Pyruvate Dehydrogenase Kinase 4 Deficiency Results in Expedited Cellular Proliferation through E2F1-Mediated Increase of Cyclins.

Authors:  Jonathan Choiniere; Jianguo Wu; Li Wang
Journal:  Mol Pharmacol       Date:  2016-12-21       Impact factor: 4.436

5.  Preserving LXR by inhibiting T39: A step closer to treating atherosclerosis and steatohepatitis?

Authors:  Melanie Tran; Li Wang
Journal:  Hepatology       Date:  2016-12-29       Impact factor: 17.425

6.  Long Non-coding RNA in Liver Metabolism and Disease: Current Status.

Authors:  Yulan Zhao; Jianguo Wu; Suthat Liangpunsakul; Li Wang
Journal:  Liver Res       Date:  2017-12-02

7.  Metabolomics Analysis Revealed Distinct Cyclic Changes of Metabolites Altered by Chronic Ethanol-Plus-Binge and Shp Deficiency.

Authors:  Melanie Tran; Zhihong Yang; Suthat Liangpunsakul; Li Wang
Journal:  Alcohol Clin Exp Res       Date:  2016-10-28       Impact factor: 3.455

8.  Long noncoding RNA MEG3 induces cholestatic liver injury by interaction with PTBP1 to facilitate shp mRNA decay.

Authors:  Li Zhang; Zhihong Yang; Jocelyn Trottier; Olivier Barbier; Li Wang
Journal:  Hepatology       Date:  2016-12-24       Impact factor: 17.425

9.  REV-ERBα Activates C/EBP Homologous Protein to Control Small Heterodimer Partner-Mediated Oscillation of Alcoholic Fatty Liver.

Authors:  Zhihong Yang; Hiroyuki Tsuchiya; Yuxia Zhang; Sangmin Lee; Chune Liu; Yi Huang; Gymar M Vargas; Li Wang
Journal:  Am J Pathol       Date:  2016-09-21       Impact factor: 4.307

10.  Multi-omic Pathway and Network Analysis to Identify Biomarkers for Hepatocellular Carcinoma.

Authors:  Megan E Barefoot; Rency S Varghese; Yuan Zhou; Cristina Di Poto; Alessia Ferrarini; Habtom W Ressom
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2019-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.